Por: Takashi Yasuda, Masayuki Endoh, Daisuke Suzuki, Asio Yoshimura, Terukuni Ideura, Kozo Tamura, Kouju Kamata, Yoshiyuki Toya, Satoshi Umemura y Kenjiro Kimura for the KVT Study Group. Hypertension Research (2013) 36, 240–246.
Suppression of the renin–angiotensin system is known to slow progression of chronic kidney disease (CKD). However, few trials have been performed with Japanese patients. This study investigated whether the angiotensin receptor blocker (ARB) valsartan would delay the progression of kidney disease more effectively than conventional treatment in Japanese hypertensive patients with advanced, predialysis CKD. In a multicenter, randomized, open-label trial, 303 patients with hypertension and CKD with serum creatinine levels greater than or equal to2.0?mg?dl-1 were assigned to receive either conventional therapy plus valsartan (valsartan add-on group) or conventional therapy without ARB (control group). [Actualizado: 15 de marzo 2013]
.Por: Toshimi Sairenchi, PhD; Hiroyasu Iso, MD, PhD, MPH; Kazumasa Yamagishi, MD, PhD; Fujiko Irie, MD, PhD; Yoshiro Okubo; Junko Gunji; Takashi Muto, MD, PhD;
Hitoshi Ota, MD, PhD. Circulation. 2011; 124: 2502-2511.
It is unclear whether mild hypertensive retinopathy is a risk factor for mortality. This study examined whether mild hypertensive retinopathy could be a risk factor for cardiovascular mortality in subjects with and without.
Comentarios recientes